

#DYK
Did you know?



Prophylactic trials:

37% in Phase III, 32% in Phase II, 30% in Phase I, and 1% in Phase 0, led by COVID-19 and RSV




Therapeutic trials:

51% in Phase II, 36% in Phase I, 10% in Phase III, and 3% in Phase 0, focused on cancers




Asia-Pacific recruits ~4x faster


mRNA and viral vector platforms drive vaccine innovations



PROPHYLACTIC TRIALS:



THERAPEUTIC TRIALS:



Prophylactic vaccine trials are growing at **54.9% CAGR**, while therapeutic trials are expanding at **21.2% CAGR**



The **U.S. and China** lead in vaccine trials, followed by Australia, the UK, and Europe


Five GHTC vaccines target **TB, Zika, Lassa Fever, Nipah, and E. coli**

Gavi supports **20 vaccines**, with plans until 2030

WHO declared **Mpox a global health emergency**, boosting vaccine efforts

Evolving trial designs **enhance safety and efficiency**

Public-private partnerships and funding ensure **global health security**



The evolving vaccine landscape integrates both prophylactic and therapeutic solutions, advancing global disease management